HLTR.F Stock Overview
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HLS Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.85 |
| 52 Week High | CA$4.95 |
| 52 Week Low | CA$2.60 |
| Beta | 1.14 |
| 1 Month Change | 23.76% |
| 3 Month Change | n/a |
| 1 Year Change | -13.87% |
| 3 Year Change | -74.73% |
| 5 Year Change | -68.75% |
| Change since IPO | -40.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| HLTR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | -3.2% |
| 1Y | -13.9% | 9.7% | 19.3% |
Return vs Industry: HLTR.F underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: HLTR.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| HLTR.F volatility | |
|---|---|
| HLTR.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HLTR.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HLTR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 91 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels.
HLS Therapeutics Inc. Fundamentals Summary
| HLTR.F fundamental statistics | |
|---|---|
| Market cap | US$114.79m |
| Earnings (TTM) | -US$27.53m |
| Revenue (TTM) | US$63.07m |
1.8x
P/S Ratio-4.2x
P/E RatioIs HLTR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLTR.F income statement (TTM) | |
|---|---|
| Revenue | US$63.07m |
| Cost of Revenue | US$13.20m |
| Gross Profit | US$49.88m |
| Other Expenses | US$77.41m |
| Earnings | -US$27.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 79.08% |
| Net Profit Margin | -43.65% |
| Debt/Equity Ratio | 88.8% |
How did HLTR.F perform over the long term?
See historical performance and comparison